2022-01-01
HTE 3.0 aims to support clinicians in the detection of patients with dyslipidemia, especially patients with familial hypercholesterolemia (FH), and in the recommendation of personalized lipid-lowering treatments. The core of HTE 3.0 is a clinical decision support system in which several knowledge-based systems are serialized: patient detection, therapeutic target setting, personalized treatment assessment, and treatment combination and prioritization, according to different criteria. The experimental evaluation of HTE 3.0 shows that the use of HTE 3.0 would mean increasing the capacity to detect FH by 5.7 times compared with usual clinical practice. Regarding the lipid-lowering treatment, a comparison of 18 cases among seven lipidologists shows that the differences between treatments provided by HTE 3.0 and human lipidologists are smaller than the differences between human experts
This work has been developed with the support of the research group SITES awarded with distinction by the Generalitat de Catalunya(2017 SGR 1551)
Open Access funding provided thanks to the CRUE-CSIC agreement with Wiley
Artículo
Versión publicada
peer-reviewed
Inglés
Hipercolesterolèmia; Hypercholesteremia; Lípids -- Metabolisme -- Trastorns; Lipids -- Metabolism -- Disorders; Intel·ligència artificial -- Aplicacions a la medicina; Artificial intelligence -- Medical applications; Sistemes d'ajuda a la decisió; Decision support systems; Diagnòstic -- Presa de decisions; Diagnosis -- Decision making
Wiley
info:eu-repo/semantics/altIdentifier/doi/10.1111/exsy.12835
info:eu-repo/semantics/altIdentifier/issn/0266-4720
info:eu-repo/semantics/altIdentifier/eissn/1468-0394
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/